167 related articles for article (PubMed ID: 17975661)
1. Gut instincts: CYP3A4 and intestinal drug metabolism.
Thummel KE
J Clin Invest; 2007 Nov; 117(11):3173-6. PubMed ID: 17975661
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
3. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
van Herwaarden AE; Wagenaar E; van der Kruijssen CM; van Waterschoot RA; Smit JW; Song JY; van der Valk MA; van Tellingen O; van der Hoorn JW; Rosing H; Beijnen JH; Schinkel AH
J Clin Invest; 2007 Nov; 117(11):3583-92. PubMed ID: 17975676
[TBL] [Abstract][Full Text] [Related]
4. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
[TBL] [Abstract][Full Text] [Related]
5. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
6. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
7. Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel.
Paolini M; Poul L; Berjaud C; Germain M; Darmon A; Bergère M; Pottier A; Levy L; Vibert E
Int J Nanomedicine; 2017; 12():5537-5556. PubMed ID: 28814868
[TBL] [Abstract][Full Text] [Related]
8. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
9. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Bardelmeijer HA; Ouwehand M; Buckle T; Huisman MT; Schellens JH; Beijnen JH; van Tellingen O
Cancer Res; 2002 Nov; 62(21):6158-64. PubMed ID: 12414642
[TBL] [Abstract][Full Text] [Related]
10. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
11. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
[TBL] [Abstract][Full Text] [Related]
12. Modulation of oral bioavailability of anticancer drugs: from mouse to man.
Schellens JH; Malingré MM; Kruijtzer CM; Bardelmeijer HA; van Tellingen O; Schinkel AH; Beijnen JH
Eur J Pharm Sci; 2000 Dec; 12(2):103-10. PubMed ID: 11102737
[TBL] [Abstract][Full Text] [Related]
13. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.
Koolen SL; van Waterschoot RA; van Tellingen O; Schinkel AH; Beijnen JH; Schellens JH; Huitema AD
J Clin Pharmacol; 2012 Mar; 52(3):370-80. PubMed ID: 21505085
[TBL] [Abstract][Full Text] [Related]
14. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
Hendrikx JJ; Lagas JS; Song JY; Rosing H; Schellens JH; Beijnen JH; Rottenberg S; Schinkel AH
Int J Cancer; 2016 Feb; 138(3):758-69. PubMed ID: 26297509
[TBL] [Abstract][Full Text] [Related]
16. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
[TBL] [Abstract][Full Text] [Related]
17. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel.
Mooiman KD; Maas-Bakker RF; Hendrikx JJ; Bank PC; Rosing H; Beijnen JH; Schellens JH; Meijerman I
J Pharm Pharmacol; 2014 Jun; 66(6):865-74. PubMed ID: 24392691
[TBL] [Abstract][Full Text] [Related]
18. Development of Caco-2 cells expressing four CYPs via a mammalian artificial chromosome.
Ohta Y; Kazuki K; Abe S; Oshimura M; Kobayashi K; Kazuki Y
BMC Biotechnol; 2020 Aug; 20(1):44. PubMed ID: 32819341
[TBL] [Abstract][Full Text] [Related]
19. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
Galetin A; Hinton LK; Burt H; Obach RS; Houston JB
Curr Drug Metab; 2007 Oct; 8(7):685-93. PubMed ID: 17979656
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.
Shen DD; Kunze KL; Thummel KE
Adv Drug Deliv Rev; 1997 Sep; 27(2-3):99-127. PubMed ID: 10837554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
